Oral Contraceptives and Breast Cancer: A review

References

• Vessey MP. Exogenous hormones in the aetiology of cancer in women. J Royal Soc Med 1984; 77: 542–9
   PubMed Web of Science ®Google Scholar
• Thomas D. Do hormones cause breast cancer?. Cancer 1984; 53: 595–604
   PubMed Web of Science ®Google Scholar
• Russo J., Tai I., Russo I. Differentiation of the mammary gland and susceptibility of carcinogenesis. Breast Cancer Res Treat 1982; 2: 5–73
   PubMedGoogle Scholar
• Russo J., Calaf G., Roi L., Russo IH. Influence of age and gland topography on cell kinetics of normal human breast tissue. JNCI 1987; 78: 413–8
   PubMedGoogle Scholar
• Henderson BE. Hormones as a cause of human cancer. Accomplishments in Cancer Research 1984 Prize Year. General Motors/Cancer Research Foundation, J. G Fortuner, J. E Rhoades. Lippincott Co, Philadelphia 1985; 153–69
   Google Scholar
• Calaf G., Martinez F., Russo I. H, et al. Age related variations in growth kinetics of primary human breast cell cultures. Int Res Commun System Med Sci 1982; 10: 551–2
   Google Scholar
• Russo J., Russo IH. Susceptibility of the mammary gland to carcinogenesis. Am J Pathol 1980; 100: 497–512
   PubMed Web of Science ®Google Scholar
• Boice J. (1981) Risk estimates for breast cancer. In: Critical issues in setting radiation dose limits. Proceedings of the 7th annual meeting. 8–9th April, 1981. National Council on Radiation Protection and Measurements, Bethesda Md, 164–81
   Google Scholar
• Tokunaga M., Norman J. E, Asano, et al. Malignant breast tumours among atomic bomb survivors. Hiroshima and Nagasaki. JNCI 1979; 6: 1347–59
   Google Scholar
• Kalache A., Vessey M. Risk factors of breast cancer. Clin Oncol 1982; 1: 661–78
   Google Scholar
• Vorherr H., Messer RH. Breast cancer: Potentially predisposing and protective factors. Am J Obstet Gynecol 1978; 130: 335–58
   PubMed Web of Science ®Google Scholar
• Battersby S., Anderson T. J, King R. JB, et al. Influence of oral contraceptives on normal human breast epithelial proliferation. J Steroid Biochemistry 1987; 28: 4, Suppl
   Google Scholar
• Ferguson D. JP, Anderson TJ. Morphological evaluation of cell turnover in relation to the menstrual cycle in the 'resting' human breast. Br J Cancer 1981; 44: 177–81
   PubMed Web of Science ®Google Scholar
• Olsson H., Landin Olsson M., Gullberg B. Retrospective assessment of menstrual cycle length in patients with breast cancer, in patients with benign breast disease, and in women without breast disease. JNCI 1983; 70: 17–20
   PubMedGoogle Scholar
• Henderson B. E, Ross R. K, Judd H. L, Krailo M. D, Pike MC. Do regular cycles increase breast cancer risk?. Cancer 1985; 56: 1206–8
   PubMed Web of Science ®Google Scholar
• Olsson H., Ranstam J., Landin-Olsson M. The number of menstrual cycles prior to the first full term pregnancy—an important risk factor of breast cancer?. Acta Oncol 1987; 5: 387–9
   Google Scholar
• La Vecchia C., De Carli A., Di Pietro S., et al. Menstrual cycle patterns and the risk of breast disease. Eur J Cancer Clin Oncol 1985; 4: 417–22
   Google Scholar
• Bernstein L., Ross R. K, Lobo R., et al. The effects of moderate physical activity on menstrual cycle patterns in adolescence: Implications for breast cancer prevention. Br J Cancer 1987; 55: 681–5
   PubMed Web of Science ®Google Scholar
• Frisch R. E, Wyshak G., Albright N. L, et al. Lower prevalence of breast cancer and cancers of the reproductive system among former college athletes compared to non-athletes. Br J Cancer 1985; 52: 885–91
   PubMed Web of Science ®Google Scholar
• Ewertz M. Effects of parity on breast cancer risk in Denmark. IV EORTC Breast Cancer Working Conference. Imperial College, London 30 June-3 July, 1987, Abstract
   Google Scholar
• Hadjimichael O. C, Boyle C. A, Meigs JW. Abortions before first love birth and risk of breast cancer. Br J Cancer 1986; 53: 281–4
   PubMedGoogle Scholar
• Pike M. C, Henderson B. E, Casagrande J. T, Rosario I., Gray GE. Oral contraceptive use and early abortion as risk factors for breast cancer in young women. Br J Cancer 1981; 43: 72–6
   PubMed Web of Science ®Google Scholar
• Reichlin S. Neuroendocrinology. Textbook of Endocrinology, R. Williams. WB Saunders, Philadelphia 1981; 589–445
   Google Scholar
• Mioduszewska O., Koszarowski T., Gorski C. The influence of hormones on breast cancer in vitro in relation to the clinical course of the disease. Prognostic factors in breast cancer, Proceedings of first Tenovus Symposium. Cardiff, A. PM Forrest, P. B Kunkler. Williams & Wilkins Company, Baltimore, MD April 12–14, 1968; 1967, 347–353
   Google Scholar
• Olsson H., Ewers S-B, Landin Olsson M., Ranstam J. Relation between tumour size and plasma prolactin levels in premenopausal patients with breast carcinoma. A preliminary report. Acta Radiol Oncol 1985; 24: 57–9
   PubMed Web of Science ®Google Scholar
• Olsson H., Borg Å, Ewers S-B, Fernö M, Möller T., Ranstam J. A biological marker strongly associated with early oral contraceptive use, for the selection of a high risk group for premenopausal breast cancer. Med Oncol Tumor Pharmacother 1986; 3: 77–81
   PubMedGoogle Scholar
• Olsson H., Alm P., Aspegren K., et al. Increased plasma prolactin levels in a group of men with breast cancer. Abstract ECCO. Stockholm 1985; 3: 69
   Google Scholar
• Olsson H., Lindahl B., Ranstam J., Borg Å, Fernö M, Norgren A. Permanent alterations induced in plasma prolactin and estrogen receptor concentration in benign and malignant tissue of women who started oral contraceptive use at an early age. Anticancer Res 1987; 7: 853–6
   PubMedGoogle Scholar
• Bani I. A, Williams C. M, Boulter P. S, Dickerson J. WT. Plasma lipids and prolactin in patients with breast cancer. Br J Cancer 1986; 54: 439–46
   PubMed Web of Science ®Google Scholar
• Bulbrook R. D, Hayward J. L, Wang D. Y, et al. Identification of women at high risk of breast cancer. Breast Cancer Res Treat 1986; 7: 5–10, Suppl
   PubMedGoogle Scholar
• Dowsett M., McGarrick G. E, Harrisa A. L, et al. Prognostic significance of serum prolactin levels in advanced breast cancer. Br J Cancer 1983; 47: 763–9
   PubMedGoogle Scholar
• Holtkamp W., Nagel G. A, Wander H. E, et al. Hyperprolactinemia is an indicator of progressive disease and poor prognosis in advanced breast cancer. Int J Cancer 1984; 34: 323–8
   PubMedGoogle Scholar
• Kwa H. G, Cleton F., Bulbrook R. D, et al. Plasma prolactin levels and breast cancer: relation to parity, weight and height, and age at first birth. Int J Cancer 1981; 28: 31–4
   PubMedGoogle Scholar
• Musey V. C, Collins D. C, Musey P. I, et al. Long term effects of a first pregnancy on the secretion of prolactin. N Engl J Med 1987; 316: 229–34
   PubMedGoogle Scholar
• Yu M. C, Gerkins R., Henderson B. E, et al. Elevated levels of prolactin in nulliparous women. Br J Cancer 1981; 43: 826–31
   PubMedGoogle Scholar
• Olsson H., Alm P., Kristoffersson U., et al. Hypophyseal tumor and gynecomastia preceding bilateral breast cancer development in a man. Cancer 1984; 53: 1974–7
   PubMedGoogle Scholar
• Olsson H., Ranstam J. Head trauma and exposure to prolactin elevating drugs as risk factors for male breast cancer. JNCI 1988; 80: 679–83
   PubMedGoogle Scholar
• Kleinberg D. L. Prolactin and breast cancer (editorial). N Engl J Med 1987; 316: 269–71
   PubMedGoogle Scholar
• Armstrong B., Sterns N., Doll R. Retrospective study of the association between the use of rauwolfia derivates and breast cancer in English women. Lancet 1974; 2: 672–5
   PubMed Web of Science ®Google Scholar
• Boston Collaborative Drug Surveillance Programme. Reserpine and breast cancer. Lancet 1974; 2: 669–71
   PubMedGoogle Scholar
• Heinonen O. P, Tuominen L., Shapiro S., et al. Reserpine and its relation to breast cancer. Lancet 1974; 2: 675–7
   PubMed Web of Science ®Google Scholar
• Kodlin D., McCarthy N. Reserpine and breast cancer. Cancer 1978; 41: 761–8
   PubMedGoogle Scholar
• Lilienfeld A. M, Chang L., Thomas D., et al. Rauwolfia derivates and breast cancer. Johns Hopkins Med J 1975; 139: 41–50
   Google Scholar
• Wilson R. G, Fornet A. P, Boyns A. R, . Phenothiazines and breast cancer. Human prolactin, Proceedings of the International Symposium on Human Prolactin, Brussels., J. L Pasteels, C. Robyn, F. JG Ebling, et al. Excerpta Medica, Elsevier Publ Co, Amsterdam 1973; 266–7
   Google Scholar
• Koscielny S., Tubiana M., Valleron AJ. A simulation model of the natural history of human breast cancer. Br J Cancer 1985; 52: 515–24
   PubMedGoogle Scholar
• Fournier D. V, Weber W., Hoefflen W., et al. Growth rate of 147 mammary carcinoma. Cancer 1980; 45: 2198–207
   PubMedGoogle Scholar
• Thomas D. Hormones and hormone receptors in the etiology of breast cancer. Breast Cancer Res Treat 1986; 7: 11–22, Suppl
   Web of Science ®Google Scholar
• McPherson K., Coope P. A, Vessey MP. Early oral contraceptive use and breast cancer: theoretical effects of latency. J Epidemiol Community Health 1986; 40: 289–94
   PubMedGoogle Scholar
• Krailo M., Thomas D. C, Pike MC. Fitting models of carcinogenesis to a case-control study of breast cancer. J Chron Dis 1987; 40: 181–9S, Suppl
   Google Scholar
• Anonymus, Another look at the pill and breast cancer. Lancet 1985; 2: 985–7
   PubMedGoogle Scholar
• Aved BM. Patterns of contraceptive method of use by California family planning clients, 1976–1984. Am J Publ Health 1985; 75: 1210–2
   PubMed Web of Science ®Google Scholar
• Dryfoos JG. Contraceptive use, pregnancy intentions and pregnancy outcomes among US women. Fam Plann Persp 1982; 14: 81–94
   PubMedGoogle Scholar
• Dunnel K. Family formation 1976. Office of Population Censuses and Surveys (HM Stationary Office), London 1979
   Google Scholar
• Forrest D. J, Henshaw SK. What US women think and do about contraception. Fam Plann Persp 1983; 15: 157–66
   PubMedGoogle Scholar
• Piper J. M, Kennedy DL. Oral contraceptives in the United States: Trends in content and potency. Int J Epidemiol 1987; 16: 215–21
   PubMedGoogle Scholar
• Russell-Briefel R., Ezzati T., Perlman J. Prevalence and trends in oral contraceptive use in premenopausal females aged 12–54 years, United States, 1971–80. Am J Public Health 1985; 75: 1173–6
   PubMedGoogle Scholar
• Zelnik M., Kantner JF. Sexual activity, contraceptive use and pregnancy among metropolitan-area teenagers 1971–1979. Fam Plann Persp 1980; 12: 231–7
   Google Scholar
• Hormonal anticonception. National Board of Health, Stockholm 1984
   Google Scholar
• Baksaas I., Lund E. Forbruket av p-piller och insidens av brystkreft. Tidsskr Nord Laegeforen 1984; 22: 1390–2
   Google Scholar
• Ranstam J., Olsson H. Oral contraceptives and breast cancer. Lancet 1987; 1: 636
   PubMedGoogle Scholar
• La Vecchia C., Decarli A., Fasoli M., et al. Oral contraceptives and cancer of the breast and of the female genital tract. Interim results from a case-control study. Br J Cancer 1986; 54: 311–7
   PubMedGoogle Scholar
• Le M. G, Bachelot A., Doyon F., Kramar A., Hill C. Oral contraceptive use and breast cancer or cervical cancer: Preliminary results of a French case-control study. Hormones and Sexual Factors in Human Cancer Aetiology, Wolf, Scott. Elsevier Sci Publ, Amsterdam 1984
   Google Scholar
• Skegg D. CG. Potential for bias in case-control studies of oral contraceptives and breast cancer (Review). Am J Epidemiol 1988; 127: 205–12
   PubMed Web of Science ®Google Scholar
• Swan S. H, Pettiti D. A review of problems of bias and confounding in epidemiologic studies of cervical neoplasia and oral contraceptive use. Am J Epidemiol 1982; 115: 10–8
   PubMedGoogle Scholar
• Coulter A., Vessey M., McPherson K. The ability of women to recall their oral contraceptive histories. Contraception 1986; 2: 127–37
   Google Scholar
• McPherson K., Vessey M. P, Neil A., et al. Early oral contraceptive use and breast cancer. Results of another case-control study. Br J Cancer 1987; 5: 653–60
   Google Scholar
• Van Leeuwen F. E, Van Duyn C., Mulder H., et al (1985) A comparison of exposure data from different sources: user/prescriber agreement on histories of oral contraceptive use. IVth EORTC Breast Cancer Working Conference. 1985. Imperial College, London, Abstract Bl. 11.
   Google Scholar
• McTiernan A., Thomas D. B, Johnsson L. K, Roseman D. Risk factors for estrogen receptor-rich and estrogen receptor-poor breast cancer. JNCI 1986; 77: 849–54
   PubMedGoogle Scholar
• Ravnihar B., Primic Zakely M., Kosmelj K., Stare J. A case-control study of breast cancer in relation to oral contraceptive use in Slovenia. Neoplasma 1988; 1: 109–21
   Google Scholar
• Olsson H., Möller T. R, Ranstam J., Borg Å, Fernö M. Early oral contraceptive use as a prognostic factor in breast cancer. Anticancer Res 1988; 8: 29–32
   PubMedGoogle Scholar
• Paffenbarger R. S, Fasal E., Simmons M. E, Kampert JB. Cancer risk as related to use of oral contraceptives during fertile years. Cancer 1977; 39: 1887–91
   PubMedGoogle Scholar
• Pike M. C, Henderson B. E, Krailo M. D, Duke A. Breast cancer in young women and use of oral contraceptives: Possible effect of formulation and age at use. Lancet 1983; 2: 926–9
   PubMed Web of Science ®Google Scholar
• McPherson K., Neil A., Vessey M. P, Doll R. Oral contraceptives and breast cancer. Lancet 1983; 1: 1414–5
   Google Scholar
• Olsson H., Landin Olsson M., Möller T., Ranstam J., Holm P. Oral contraceptive use and breast cancer in young women in Sweden. Lancet 1985; 2: 748–9
   Google Scholar
• Olsson H., Möller T. R, Ranstam J. P-pilleranvändning och bröstcancer (Review). Läkartidningen 1985; 39: 3277–8
   Google Scholar
• Kelsey J. L, Holford T. R, White C., Mayer E. S, Kilty S. E, Acheson RM. Oral contraceptives and breast disease. Am J Epidemiol 1978; 107: 236–44
   PubMedGoogle Scholar
• Ravnihar B., Seigel D. G, Lindtner J. An epidemiologic study of breast cancer and benign breast neoplasia in relation to the oral contraceptive and estrogen use. Eur J Cancer 1979; 15: 395–405
   Google Scholar
• Sartwell P. E, Arthes F. G, Tonascia JA. Exogenous hormones, reproductive history, and breast cancer. JNCI 1977; 59: 1589–92
   PubMedGoogle Scholar
• Trapido EJ. A prospective cohort study of oral contraceptives and breast cancer. JNCI 1981; 67: 1011–5
   PubMedGoogle Scholar
• Vessey M. P, McPherson K., Doll R. Breast cancer and oral contraceptives: findings in Oxford-Family Planning Association contraceptive study. Br Med J 1981; 282: 2093–4
   PubMedGoogle Scholar
• Brinton L. A, Williams R. R, Hoover R. N, et al. Breast cancer risk factors among program participants. JNCI 1979; 62: 37–43
   PubMedGoogle Scholar
• Brinton L. A, Hoover R., Szklo M., Fraumeni JF. Oral contraceptives and breast cancer. Int J Epidemiol 1982; 11: 316–22
   PubMedGoogle Scholar
• Clavel F., Le M., Laplanche A. Etude de la liasion entre le cancer du sein et la prise de medicaments hypotenseures et contraceptifs oraux: Resultats d'une étude cas-temoins. Bull Cancer 1981; 68: 449–55
   PubMedGoogle Scholar
• Harris N. V, Weiss N. S, Francis A. M, Polissar L. Breast cancer in relation to patterns of oral contraceptive use. Am J Epidemiol 1982; 116: 643–51
   PubMed Web of Science ®Google Scholar
• Hennekens C. H, Speizer F. E, Lipnick R. J, et al. A case-control study of oral contraceptive use and breast cancer. JNCI 1984; 72: 39–42
   PubMedGoogle Scholar
• Janerich T. D, Polednak A. P, Glebtis M. D, Lawrence CE. Breast cancer and oral contraceptive use: A case-control study. J Chron Dis 1983; 36: 639–46
   PubMedGoogle Scholar
• Jick H., Walker A. M, Watkins R. N, et al. Oral contraceptives and breast cancer. Am J Epidemiol 1980; 112: 577–85
   PubMed Web of Science ®Google Scholar
• Lees A. W, Burns P. E, Grace M. Oral contraceptives and breast cancer disease in premenopausal northern Albertan women. Int J Cancer 1978; 22: 700–7
   PubMedGoogle Scholar
• Paffenbarger R. S, Kampert J. B, Chang HG. Oral contraceptives and breast cancer risk. INSERM 1979; 83: 93–114
   Google Scholar
• Rosenberg L., Miller D. R, Kaufman D. W, et al. Breast cancer and oral contraceptive use. Am J Epidemiol 1984; 119: 167–76
   PubMedGoogle Scholar
• Royal College of General Practitioners Breast cancer and oral contraceptives: findings in Royal College of General Practitioners study. Br Med J 1981; 282: 2089–93
   PubMedGoogle Scholar
• The Centers for Disease Control Cancer and Steroid Hormone Study. Long-term oral contraceptive use and the risk of breast cancer. JAMA 1983; 249: 1591–5
   PubMed Web of Science ®Google Scholar
• Dubin N., Hutter R. UP, Strax P., et al. Epidemiology and minimal breast cancer among women screened in New York City. JNCI 1984; 73: 1273–9
   PubMedGoogle Scholar
• Vessey M. P, McPherson K., Yeates D., Doll R. Oral contraceptive use and abortion before first full term pregnancy in relation to breast cancer. Br J Cancer 1982; 45: 327–31
   PubMedGoogle Scholar
• Vessey M., Baron J., Doll R., McPherson K., Yeates D. Oral contraceptives and breast cancer: Final report of an epidemiological study. Br J Cancer 1983; 47: 455–62
   PubMed Web of Science ®Google Scholar
• Ramcharan S., Pellegrin F. A, Ray R., Hsu JP. The Walnut Creek Contraceptive Drug Study—A prospective study on the side effects of oral contraceptives. J Reprod Med 1980; 25: 345–72, Suppl
   PubMedGoogle Scholar
• Lipnick R. J, Buring J. E, Hennekens C. H, et al. Oral contraceptives and breast cancer. A prospective cohort study. JAMA 1986; 255: 58–61
   PubMedGoogle Scholar
• Miller D. R, Rosenberg L., Kaufrnan D. W, et al. Breast cancer risk in relation to early oral contraceptive use. Obstet Gynecol 1986; 68: 863–8
   PubMedGoogle Scholar
• Stadel B. V, Rubin G. L, Webster L. A, Schlesselman J. J, Wingo PA. Oral contraceptives and breast cancer in young women. Lancet 1985; 2: 970–3
   PubMedGoogle Scholar
• Ellery C, Maclennan R., Berry G., Shearman RP. A case-control study of breast cancer in relation to the use of steroid contraceptive agents. Med J Aust 1986; 144: 173–6
   PubMed Web of Science ®Google Scholar
• Paul C., Skegg D. CG, Spears G. FS, Kaldor JM. Oral contraceptives and breast cancer: a national study. Br Med J 1986; 293: 723–6
   PubMedGoogle Scholar
• Meirik O., Lund E., Adami H. O, Bergström R., Christofferson T., Bergsjö P. Oral contraceptive use and breast cancer in young women. A joint national case-control study in Sweden and Norway. Lancet 1986; 2: 650–3
   PubMed Web of Science ®Google Scholar
• Alexander F. E, Roberts M. M, Huggins A. Risk factors for breast cancer with applications to selection for the prevalence screen. J Epidem Community Health 1987; 41: 101–6
   PubMedGoogle Scholar
• Lee N. C, Rosero-Bixby L., Oberle M. W, et al. A case-control study of breast cancer and hormonal contraception in Costa Rica. JNCI 1987; 79: 1247–54
   PubMed Web of Science ®Google Scholar
• Adami H. O, Meirik O., Lund E. Nya rön om p-piller och bröstcancer. Läkartidningen 1986; 38: 3086–7
   Google Scholar
• Adami H. O, Meirik O., Bergström R., Lund E. Replik. Läkartidningen 1987; 43: 3471
   Google Scholar
• Ahlbom A., Norell S. Motstridiga resultat i olika undersökningar. Läkartidningen 1986; 48: 4077
   Google Scholar
• Ahlbom A., Norell SE. Oral contraceptives and breast cancer. Lancet 1986; 2: 923
   PubMedGoogle Scholar
• McPherson K., Drife JO. The pill and breast cancer: why the uncertainty? Editorial. Br Med J 1986; 20: 709–10
   Google Scholar
• Meirik O., Adami H. O, Lund E. Replik. Läkartidningen 1986; 48: 4077–8
   Google Scholar
• Meirik O., Lund E., Adami HO. Oral contraceptives and breast cancer. Lancet 1986; 2: 1272–3
   PubMedGoogle Scholar
• Meirik O., Lund E., Adami H. O, et al. Oral contraceptives and breast cancer. Lancet 1987; 1: 1042
   PubMedGoogle Scholar
• Ranstam J., Olsson H., Möller T. Är det tidig eller långvarig användning av p-piller som ger en ökad risk för bröstcancer?. Läkartidningen 1986; 48: 4075–6
   Google Scholar
• Ranstam J., Olsson H. Motsägande uppgifter i den svensknorska studien. Läkartidningen 1987; 43: 3471
   Google Scholar
• Ranstam J., Möller T. R, Olsson H. Oral contraceptives and breast cancer. Lancet 1986; 2: 923
   PubMedGoogle Scholar
• Stadel B. V, Schlesselman JJ. Oral contraceptives and breast cancer. Lancet 1986; 2: 922–3
   PubMedGoogle Scholar
• Westerholm B. P-pilleranvändning och bröstcancemsk. De nya rönen gäller gårdagens preparat. Läkartidningen 1986; 48: 4072–5
   Google Scholar
• Schlesselman J. J, Stadel B. V, Murray P., Wingo P. A, Rubin SL. Consistency and plausibility in epidemiological analysis: Application to breast cancer in relation to use of oral contraceptives. J Chron Dis 1987; 11: 1033–9
   Google Scholar
• Schlesselman J. J, Stadel B. V, Murray P., Lai S. Breast cancer in relation to early use of oral contraceptives. No evidence of a latent effect. JAMA 1988; 259: 1828–33
   PubMed Web of Science ®Google Scholar
• Cancer the Steroid Hormone Study of the Centers of Control Disease the National Institute of Health Child. Human Development. Oral contraceptive use and risk of breast cancer. N Engl J Med 1986; 315: 405–11
   PubMed Web of Science ®Google Scholar
• McPherson K., Coope PA. Early oral contraceptive use and breast cancer risk. Lancet 1986; 1: 685–6
   PubMedGoogle Scholar
• Olsson H., Ranstam J., Möller TR. Breast cancer and oral contraceptives. Lancet 1985; 2: 1181
   Google Scholar
• Ranstam J., Olsson H., Möller T. Oral contraceptive use and the risk of breast cancer. N Engl J Med 1987; 316: 162
   PubMedGoogle Scholar
• Pike MC. Breast cancer and oral contraceptives. Lancet 1985; 2: 1180–1
   Google Scholar
• Ewertz M. Oral contraceptives and breast cancer. Presented at the IACR meeting. Copenhagen August, 1987
   Google Scholar
• Shubik P. Oral contraceptives and breast cancer. Laboratory evidence. Interpretation of negative epidemiological evidence for carcinogenicity, N. J Wald, R. Doll, Lyon 1985; 33–6, IARC Scientific Publication No 65
   Google Scholar
• Lemon H. Antimammary carcinogenic activity of 17-alpha-ethinyl estriol. Cancer 1987; 60: 2873–81
   PubMedGoogle Scholar
• Key T. JA, Pike MC. The role of oestrogens and progesta-gens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol 1988; 24: 2943
   Google Scholar
• Swyer G. IM. Progestagen 'potency' and breast cancer. Lancet 1983; 2: 1416
   PubMedGoogle Scholar
• Black M. M, Barclay T. HC, Polednak A., et al. Family history, oral contraceptive use and breast cancer. Cancer 1983; 51: 2147–51
   PubMedGoogle Scholar
• Greenberg E. R, Vessey M. P, McPherson K., Yeates D. Body size and survival in premenopausal breast cancer. Br J Cancer 1985; 51: 691–7
   PubMed Web of Science ®Google Scholar
• Matthews P. N, Millis R. R, Hayward JL. Breast cancer in women who have taken the contraceptive steroids. Br Med J 1981; 282: 7746
   Google Scholar
• Millard F. C, Bliss J. M, Chilvers C. ED, Gazet JC. Oral contraceptives and survival in breast cancer. Br J Cancer 1987; 56: 377–8
   PubMedGoogle Scholar
• Rosner D., Lane W. W, Brett RP. Influence of oral contraceptives on the prognosis of breast cancer in young women. Cancer 1985; 55: 155–2
   Google Scholar
• Rosner D. H, Joy J. V, Lane WW. Oral contraceptives and prognosis of breast cancer in women aged 35–50. J Surg Oncol 1985; 30: 52–9
   PubMedGoogle Scholar
• Spencer J. D, Millis R. R, Hayward JL. Contraceptive steroids and breast cancer. Br Med J 1978; 1: 1024–6
   PubMedGoogle Scholar
• Olsson H., Moller TR., Ranstam J., et al. Early oral contraceptive use as a prognostic factor in breast cancer. J Steroid Biochemistry 1987; 28: 55s, Suppl
   PubMedGoogle Scholar
• White E., Daling J. R, Norstedt T. L, Chu J. Rising incidence of breast cancer among young women in Washington State. JNCI 1987; 79: 239–43
   PubMedGoogle Scholar
• National Cancer Institute 1986 Annual Cancer Statistics Review. 1986, NIH-publication 87–2789. III. A. 2
   Google Scholar
• Anonymous. News. New Cancer Statistics Released. JNCI 1988; 80: 8
   Google Scholar
• Krieger N. Rising incidence of breast cancer. JNCI 1988; 80: 2
   PubMedGoogle Scholar
• White E. Response. JNCI 1988; 80: 2–3
   PubMedGoogle Scholar
• Musey V. C, Collins D. C, Brogan D. R, et al. Long term effect of a first pregnancy on the hormonal environment: estrogens and androgens. J Clin Endocrinol Metab 1987; 64: 111–8
   PubMed Web of Science ®Google Scholar
• Ernster V. L, Wrensch M. R, Petrakis N., et al. Benign and malignant breast disease: Initial study results of serum and breast fluid analyses of endogenous estrogens. JNCI 1987; 79: 94960
   Google Scholar
• Petrakis N., Wrensch M. R, Ernster V. L, et al. Influence of pregnancy and lactation on serum and breast fluid estrogen levels: Implications for breast cancer risk. Int J Cancer 1987; 40: 587–91
   PubMed Web of Science ®Google Scholar
• Hulka B. S, Chambless L. E, Wilkinson W. E, et al. Hormonal and personal effects on estrogen receptors in breast cancer. Am J Epidemiol 1984; 119: 692–704
   PubMed Web of Science ®Google Scholar
• Lesser M. L, Rosen P. P, Senie R. T, et al. Estrogen and progesterone receptors in breast carcinoma: correlations with epidemiology and pathology. Cancer 1981; 48: 299–309
   PubMed Web of Science ®Google Scholar
• Osborne M. P, Rosen P. P, Lesser M. L, et al. The relationship between family history, exposure to exogenous hormones, and estrogen receptor protein in breast cancer. Cancer 1983; 51: 2134–8
   PubMed Web of Science ®Google Scholar
• Stanford J. L, Szklo M., Boring CC, et al. A case-control study of breast cancer stratified by estrogen receptor status. Am J Epidemiol 1987; 125: 184–94
   PubMed Web of Science ®Google Scholar
• Olsson H. Reproductive events, occurring in adolescence at the time of development of reproductive organs and at the time of tumour initiation, have a bearing on growth characteristics and reproductive hormone regulation in normal and tumour tissue investigated decades later—a hypothesis. Med Hypotheses 1989; 28: 93–7
   PubMed Web of Science ®Google Scholar
• Forman D., Vincent T. J, Doll R. Cancer of the liver and the use of oral contraceptives. Br Med J 1986; 292: 1357–61
   PubMed Web of Science ®Google Scholar
• Neuberger J., Forman D., Doll R., Williams R. Oral contraceptives and hepatocellular carcinoma. Br Med J 1986; 292: 1355–7
   PubMed Web of Science ®Google Scholar
• Yen S., Hsieh C. C, MacMahon B. Extrahepatic bile duct cancer and smoking, beverage consumption, past medical history, and oral contraceptive use. Cancer 1987; 59: 2112–6
   PubMedGoogle Scholar
• Peters R. K, Chao A., Mack T., Thomas D., Bernstein L., Henderson B. Increased frequency of adenocarcinoma of the uterine cervix in young women in Los Angeles County. JNCI 1986; 76: 423–8
   PubMed Web of Science ®Google Scholar
• Schwartz S. M, Weiss NS. Increased incidence of adenocarcinoma of the cervix in young women in the United States. Am J Epidemiol 1986; 6: 1045–7
   Google Scholar
• Eide TJ. Cancer of the uterine in Norway by histologic type, 1970–1984. JNCI 1987; 79: 199–205
   PubMedGoogle Scholar
• Ebeling K., Nischan P., Schindler Ch. Use of oral contraceptives and risk of invasive cervical cancer in previously screened women. Int J Cancer 1987; 39: 427–30
   PubMedGoogle Scholar
• Brinton L., Tashima K. T, Lehman H. F, et al. Epidemiology of cervical cancer by cell type. Cancer Research 1987; 47: 1706–11
   PubMed Web of Science ®Google Scholar
• Stadel B. V, Lai S., Schlesselman J. J, Murray P. Oral contraceptives and premenopausal breast cancer in nulliparous women. Contraception 1988; 3: 287–99
   Google Scholar
• Kay C. R, Hannaford PC. Breast cancer and the pill—a further report from the Royal College of General Practitioners' oral contraceptive study. Br J Cancer 1988; 58: 675–80
   PubMed Web of Science ®Google Scholar